| Literature DB >> 26235950 |
Zhi-Liang Wei1, Margaret T Nguyen1, Donogh J R O'Mahony1, Alejandra Acevedo1, Sheila Zipfel1, Qingling Zhang1, Luna Liu1, Michelle Dourado1, Candace Chi1, Victor Yip1, Jeff DeFalco1, Amy Gustafson1, Daniel E Emerling1, Michael G Kelly1, John Kincaid1, Fabien Vincent2, Matthew A J Duncton3.
Abstract
Antagonists of the TRPV4 receptor were identified using a focused screen, followed by a limited optimization program. The leading compounds obtained from this exercise, RN-1665 23 and RN-9893 26, showed moderate oral bioavailability when dosed to rats. The lead molecule, RN-9893 26, inhibited human, rat and murine variants of TRPV4, and showed excellent selectivity over related TRP receptors, such as TRPV1, TRPV3 and TRPM8. The overall profile for RN-9893 may permit its use as a proof-of-concept probe for in vivo applications.Entities:
Keywords: Antagonist; Pain; RN-1734; RN-9893; TRPV4
Mesh:
Substances:
Year: 2015 PMID: 26235950 DOI: 10.1016/j.bmcl.2015.06.098
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823